4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology and pulmonology therapeutic areas. 4D Molecular Therapeutics Inc. is based in Emeryville, California.
| Revenue (Most Recent Fiscal Year) | $0.04M |
| Net Income (Most Recent Fiscal Year) | $-160.87M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 7875.25 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.39 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -767126.00% |
| Net Margin (Trailing 12 Months) | -767126.06% |
| Return on Equity (Trailing 12 Months) | -33.26% |
| Return on Assets (Trailing 12 Months) | -30.68% |
| Current Ratio (Most Recent Fiscal Quarter) | 12.36 |
| Quick Ratio (Most Recent Fiscal Quarter) | 12.36 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $11.05 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.86 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.98 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.18 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 46.33M |
| Free Float | 41.88M |
| Market Capitalization | $181.13M |
| Average Volume (Last 20 Days) | 0.41M |
| Beta (Past 60 Months) | 2.84 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 9.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 99.27% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |